In the positive control analysis, we observed significant associations between genetically proxied drug targets and lower risk of CAD, indicating the genetic instruments with good validity, except for genetically proxied inhibition of CACNA1D (ebi-a-GCST90029011), which showed a tendency towards protection but without statistical significance (OR = 0.586, 95% CI: 0.341-1.006, P = 0.053) (Figure 2). The gene discussed is CACNA1D; the disease is coronary artery disorder.